Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
| العنوان: | Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection |
|---|---|
| المؤلفون: | Escudero-Sánchez R, Ruíz-Ruizgómez M, Fernández-Fradejas J, García Fernández S, Olmedo Samperio M, Cano Yuste A, Valencia Alijo A, Díaz-Pollán B, Rodríguez Hernández MJ, Merino De Lucas E, Martín Segarra O, Sáez Bejar C, Armiñanzas Castillo C, Gutiérrez Gutiérrez B, Rodríguez-Pardo D, Ramos Martínez A, De La Torre Cisneros J, López-Medrano F, Cobo Reinoso J |
| المصدر: | Journal of Clinical Medicine r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante instname |
| بيانات النشر: | MDPI, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | C. difficile infection, recurrence, Clostridioides difficile, Clostridium difficile, bezlotoxumab |
| الوصف: | Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezlotoxumab in preventing rCDI and to investigate factors related to bezlotoxumab failure in the real world. A retrospective, multicentre cohort study of patients treated with bezlotoxumab in Spain was conducted. We compared the characteristics of cohort patients with those of patients treated with bezlotoxumab in the pivotal MODIFY trials. We assessed recurrence rates 12 weeks after completion of treatment against C. difficile, and we analysed the factors associated with bezlotoxumab failure. Ninety-one patients were included in the study. The cohort presented with more risk factors for rCDI than the patients included in the MODIFY trials. Thirteen (14.2%) developed rCDI at 12 weeks of follow-up, and rCDI rates were numerically higher in patients with two or more previous episodes (25%) than in those who had fewer than two previous episodes of C. difficile infection (CDI) (10.4%); p = 0.09. There were no adverse effects attributable to bezlotoxumab. Despite being used in a more compromised population than that represented in clinical trials, we confirm the effectiveness of bezlotoxumab for the prevention of rCDI. |
| تدمد: | 2077-0383 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::140905e5bbb7c95b5e69e3ef0fb670ddTest https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6759Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.RECOLECTA.....140905e5bbb7c95b5e69e3ef0fb670dd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20770383 |
|---|